Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$116.17 USD
+0.71 (0.61%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $116.20 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$116.17 USD
+0.71 (0.61%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $116.20 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) Hips and Knees portfolios are expected to have contributed to second-quarter top line despite pandemic-led business disruptions.
3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis
by Sriparna Ghosal
Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.
3 Affordable MedTech Growth Stocks to Buy Amid Market Unrest
by Debanjana Dey
Here are some MedTech stocks which might be a solid investment option amid the coronavirus-battered market conditions.
3 Cheap MedTech Stocks Set to Gain Once Coronavirus Crisis Ebbs
by Sriparna Ghosal
Once the pandemic-led crisis eases, these MedTech stocks will likely flourish on the back of number of positive developments.
Medical Products Industry's Near-Term Outlook Lacks Spark
by Trina Mukherjee
AI & Robotics can drive the medical products industry amid the coronavirus-induced crisis.
Zimmer Biomet Adds New Features to mymobility with Apple Watch
by Zacks Equity Research
Zimmer Biomet (ZBH) expands mymobility digital platform by leveraging Apple's ecosystem to enhance patients' post-operative care.
The Smart Future: Will Robotics Call the Shots Post Coronavirus?
by Zacks Equity Research
Robots are assisting in surprising ways on the COVID frontline. With their pivotal role in battling the coronavirus, robotics revolution is swiftly gaining momentum and soon might be the new normal.
Zimmer (ZBH) Up 18.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should iShares Morningstar MidCap Value ETF (JKI) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for JKI
Zimmer Biomet Faces Procedure Delays, Long-Term Potential Solid
by Zacks Equity Research
Zimmer Biomet (ZBH) believes COVID-19 to continue to have a significant unfavorable impact on its sales in the near term.
Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
The spread of coronavirus results in deferral of elective procedures for Zimmer Biomet (ZBH) in Q1.
Zimmer Biomet (ZBH) Beats Q1 Earnings Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 22.30% and -0.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
How Hard Will Coronavirus Hit Zimmer Biomet (Zbh) Q1 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) may have registered improved performances within its Hips and Knees arms due to the nature of the businesses.
Here's Why You Should Add Zimmer Biomet to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Zimmer Biomet (ZBH) on its strong segmental and international results in the fourth quarter of 2019.
Zimmer Biomet Grows on Strong Emerging Market, Innovation
by Zacks Equity Research
Zimmer Biomet (ZBH) solidifies its foothold in the emerging markets on strong operational and sales performance.
Should iShares Morningstar Mid-Cap Value ETF (JKI) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKI
ZBH or MDT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. MDT: Which Stock Is the Better Value Option?
Robotics & AI Make Inroads in HealthCare: Stocks to Benefit
by Sreoshi Bera
Robotics and AI make rapid advancement in the field of healthcare. Here are five stocks that you can bet on.
Align Technology to Acquire exocad in Digital Dentistry Space
by Zacks Equity Research
This acquisition is expected to boost Align Technology's (ALGN) portfolio of Invisalign and iTero digital solutions.
Why Is Zimmer (ZBH) Down 12.5% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical Products Industry Outlook: Growth Prospects Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.
Here's Why You Should Add Zimmer (ZBH) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Zimmer's (ZBH) potential on its strong segmental and international results for the fiscal fourth quarter.